Slc7a5 (solute carrier family 7 member 5) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Slc7a5 (solute carrier family 7 member 5) Rattus norvegicus
Symbol: Slc7a5
Name: solute carrier family 7 member 5
RGD ID: 620639
Description: Enables amino acid transmembrane transporter activity. Involved in several processes, including amino acid transport; cellular response to L-arginine; and liver regeneration. Located in basolateral plasma membrane and external side of apical plasma membrane. Used to study high grade glioma. Biomarker of hepatocellular carcinoma and transitional cell carcinoma. Human ortholog(s) of this gene implicated in cholangiocarcinoma; colon cancer; hepatocellular carcinoma; and lung squamous cell carcinoma. Orthologous to human SLC7A5 (solute carrier family 7 member 5); PARTICIPATES IN mTOR signaling pathway; amiloride pharmacodynamics pathway; bendroflumethiazide pharmacodynamics pathway; INTERACTS WITH 17alpha-ethynylestradiol; 17beta-estradiol; 17beta-estradiol 3-benzoate.
Type: protein-coding
Previously known as: 4F2 LC; 4F2 light chain; 4F2LC; E16; integral membrane protein E16; L-type amino acid transporter 1; large neutral amino acids transporter small subunit 1; LAT-1; solute carrier family 7 (amino acid transporter light chain, L system), member 5; solute carrier family 7 (cationic amino acid transporter, y+ system), member 5; TA1; TA1/LAT-1/CD98 light chain region; tumor-associated protein 1
RGD Orthologs
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.21949,935,220 - 49,963,823 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1949,935,220 - 49,963,823 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1956,727,676 - 56,756,167 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01957,410,169 - 57,438,773 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01959,626,276 - 59,654,767 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01954,693,959 - 54,722,563 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1954,693,959 - 54,722,563 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01965,412,970 - 65,441,647 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41952,120,728 - 52,149,332 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11952,125,608 - 52,154,213 (-)NCBI
Celera1949,180,586 - 49,208,780 (-)NCBICelera
Cytogenetic Map19q12NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Disease Annotations     Click to see Annotation Detail View

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(S)-nicotine  (ISO)
1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane  (ISO)
1,1-dichloroethene  (ISO)
1,2-dimethylhydrazine  (ISO)
1-chloro-2,4-dinitrobenzene  (ISO)
17alpha-ethynylestradiol  (EXP,ISO)
17beta-estradiol  (EXP,ISO)
17beta-estradiol 3-benzoate  (EXP)
2,2',4,4',5,5'-hexachlorobiphenyl  (EXP,ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (EXP)
2,2',5,5'-tetrachlorobiphenyl  (EXP,ISO)
2,3',4,4',5-Pentachlorobiphenyl  (EXP)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,3,7,8-Tetrachlorodibenzofuran  (EXP)
2,4-dibromophenyl 2,4,5-tribromophenyl ether  (ISO)
2,6-dinitrotoluene  (EXP)
2-methylcholine  (ISO)
3,3',4,4',5-pentachlorobiphenyl  (EXP,ISO)
3-isobutyl-1-methyl-7H-xanthine  (ISO)
4,4'-sulfonyldiphenol  (EXP,ISO)
4-(ethoxymethylene)-2-phenyloxazol-5-one  (ISO)
4-hydroxyphenyl retinamide  (ISO)
5-aza-2'-deoxycytidine  (ISO)
6-propyl-2-thiouracil  (EXP)
acrylamide  (ISO)
actinomycin D  (ISO)
afimoxifene  (ISO)
aflatoxin B1  (ISO)
Aflatoxin B2 alpha  (ISO)
all-trans-retinoic acid  (ISO)
AM-251  (ISO)
ammonium chloride  (EXP)
antimycin A  (ISO)
aristolochic acid A  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
atrazine  (ISO)
azoxystrobin  (ISO)
benzene  (ISO)
benzo[a]pyrene  (ISO)
benzo[a]pyrene diol epoxide I  (ISO)
beta-naphthoflavone  (ISO)
bexarotene  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
Bisphenol B  (ISO)
bisphenol F  (EXP,ISO)
bortezomib  (ISO)
butan-1-ol  (ISO)
cadmium dichloride  (ISO)
carbamazepine  (ISO)
carbon nanotube  (ISO)
carbonyl sulfide  (EXP)
cefaloridine  (EXP)
chloroacetaldehyde  (ISO)
chloropicrin  (ISO)
chloroprene  (ISO)
chlorpyrifos  (ISO)
cholesterol  (ISO)
chrysene  (ISO)
cidofovir anhydrous  (ISO)
cisplatin  (ISO)
clobetasol  (ISO)
clodronic acid  (ISO)
clofibrate  (ISO)
cobalt dichloride  (EXP,ISO)
colforsin daropate hydrochloride  (ISO)
coumestrol  (ISO)
crocidolite asbestos  (ISO)
Cuprizon  (EXP)
cycloheximide  (ISO)
cyclosporin A  (EXP,ISO)
daidzein  (ISO)
deguelin  (ISO)
dexamethasone  (ISO)
dextran sulfate  (ISO)
diclofenac  (ISO)
dicrotophos  (ISO)
diethylstilbestrol  (ISO)
dioxygen  (EXP,ISO)
disodium selenite  (ISO)
dorsomorphin  (ISO)
doxorubicin  (ISO)
elemental selenium  (ISO)
endosulfan  (EXP)
Enterolactone  (ISO)
entinostat  (ISO)
estrone  (ISO)
ethanol  (ISO)
ethyl methanesulfonate  (ISO)
etoposide  (ISO)
fenofibrate  (ISO)
fenpyroximate  (ISO)
flavonoids  (EXP)
flutamide  (EXP)
folic acid  (ISO)
fulvestrant  (ISO)
furan  (EXP)
gabapentin  (ISO)
genistein  (ISO)
gentamycin  (EXP)
hexane  (EXP)
hydrogen peroxide  (ISO)
ibuprofen  (ISO)
ifosfamide  (ISO)
Indeno[1,2,3-cd]pyrene  (ISO)
indometacin  (EXP,ISO)
isoniazide  (ISO)
isotretinoin  (ISO)
ivermectin  (ISO)
L-tryptophan  (ISO)
leflunomide  (ISO)
lipopolysaccharide  (ISO)
mercury atom  (ISO)
mercury dibromide  (ISO)
mercury dichloride  (EXP)
mercury(0)  (ISO)
mestranol  (ISO)
metformin  (EXP)
methamphetamine  (EXP)
methimazole  (EXP)
methyl methanesulfonate  (ISO)
methylmercury chloride  (ISO)
mitoxantrone  (ISO)
N-acetyl-beta-D-glucosamine  (ISO)
N-acetyl-D-glucosamine  (ISO)
N-methyl-4-phenylpyridinium  (EXP,ISO)
nickel atom  (ISO)
nickel dichloride  (ISO)
nickel sulfate  (ISO)
nicotine  (ISO)
ochratoxin A  (ISO)
oxaliplatin  (EXP,ISO)
ozone  (ISO)
p-chloromercuribenzoic acid  (ISO)
panobinostat  (ISO)
paracetamol  (EXP,ISO)
paraquat  (EXP)
perfluorononanoic acid  (ISO)
perfluorooctane-1-sulfonic acid  (ISO)
perfluorooctanoic acid  (ISO)
phenobarbital  (ISO)
phenylmercury acetate  (ISO)
phytoestrogen  (ISO)
picoxystrobin  (ISO)
piperonyl butoxide  (EXP)
pirinixic acid  (ISO)
piroxicam  (ISO)
potassium bromate  (ISO)
progesterone  (ISO)
pyrimidifen  (ISO)
quercetin  (ISO)
raloxifene  (ISO)
resveratrol  (ISO)
riddelliine  (EXP)
rotenone  (EXP,ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
SB 431542  (ISO)
selenium atom  (ISO)
silicon dioxide  (ISO)
sodium arsenite  (ISO)
sunitinib  (ISO)
tamoxifen  (ISO)
tebufenpyrad  (ISO)
temozolomide  (ISO)
tert-butyl hydroperoxide  (ISO)
tetrachloromethane  (ISO)
tetraphene  (ISO)
thapsigargin  (EXP,ISO)
thifluzamide  (ISO)
thioacetamide  (EXP)
titanium dioxide  (ISO)
topotecan  (EXP)
trichloroethene  (EXP)
trichostatin A  (ISO)
triphenyl phosphate  (EXP)
triticonazole  (EXP)
trovafloxacin  (ISO)
tunicamycin  (ISO)
valproic acid  (EXP,ISO)
vinclozolin  (EXP)
zearalenone  (ISO)
zidovudine  (ISO)
zoledronic acid  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process

Cellular Component


References - curated
# Reference Title Reference Citation
1. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma. Andersen M, etal., J Mol Diagn. 2014 Jul;16(4):418-30. doi: 10.1016/j.jmoldx.2014.03.002. Epub 2014 Jun 6.
2. Site-directed mutagenesis of rabbit LAT1 at amino acids 219 and 234. Boado RJ, etal., J Neurochem. 2003 Mar;84(6):1322-31. doi: 10.1046/j.1471-4159.2003.01622.x.
3. Hyperoxia inhibits nitric oxide treatment effects in alveolar epithelial cells via effects on L-type amino acid transporter-1. Brahmajothi MV, etal., Antioxid Redox Signal. 2014 Nov 1;21(13):1823-36. doi: 10.1089/ars.2013.5664. Epub 2014 Sep 22.
4. Association of 4F2hc with light chains LAT1, LAT2 or y+LAT2 requires different domains. Bröer A, etal., Biochem J. 2001 May 1;355(Pt 3):725-31. doi: 10.1042/bj3550725.
5. TA1/LAT-1/CD98 light chain and system L activity, but not 4F2/CD98 heavy chain, respond to arginine availability in rat hepatic cells. Loss Of response in tumor cells. Campbell WA, etal., J Biol Chem. 2000 Feb 25;275(8):5347-54. doi: 10.1074/jbc.275.8.5347.
6. The general amino acid control pathway regulates mTOR and autophagy during serum/glutamine starvation. Chen R, etal., J Cell Biol. 2014 Jul 21;206(2):173-82. doi: 10.1083/jcb.201403009.
7. Tissue-based metabolomics reveals metabolic biomarkers and potential therapeutic targets for esophageal squamous cell carcinoma. Chen Z, etal., J Pharm Biomed Anal. 2021 Apr 15;197:113937. doi: 10.1016/j.jpba.2021.113937. Epub 2021 Feb 5.
8. GSE1 predicts poor survival outcome in gastric cancer patients by SLC7A5 enhancement of tumor growth and metastasis. Ding K, etal., J Biol Chem. 2018 Mar 16;293(11):3949-3964. doi: 10.1074/jbc.RA117.001103. Epub 2018 Jan 24.
9. L-type amino-acid transporter 1 expression predicts the response to preoperative hyperthermo-chemoradiotherapy for advanced rectal cancer. Ebara T, etal., Anticancer Res. 2010 Oct;30(10):4223-7.
10. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
11. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
12. L-type amino acid transporter 1 expression in esophageal carcinogenesis according to WHO and Japanese classifications of intraepithelial neoplasia. Hashimoto H, etal., Pathol Int. 2017 May;67(5):247-255. doi: 10.1111/pin.12528. Epub 2017 Mar 29.
13. L-type amino acid transporter 1 expression is upregulated and associated with cellular proliferation in colorectal cancer. Hayase S, etal., Oncol Lett. 2017 Dec;14(6):7410-7416. doi: 10.3892/ol.2017.7148. Epub 2017 Oct 6.
14. Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma. Honjo H, etal., J Surg Oncol. 2016 Mar;113(4):381-9. doi: 10.1002/jso.24160. Epub 2016 Mar 3.
15. High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Ichinoe M, etal., Pathol Int. 2011 May;61(5):281-9. doi: 10.1111/j.1440-1827.2011.02650.x. Epub 2011 Mar 17.
16. L-Type amino acid transporter 1 (LAT1) expression in lymph node metastasis of gastric carcinoma: Its correlation with size of metastatic lesion and Ki-67 labeling. Ichinoe M, etal., Pathol Res Pract. 2015 Jul;211(7):533-8. doi: 10.1016/j.prp.2015.03.007. Epub 2015 Apr 7.
17. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Imai H, etal., Anticancer Res. 2010 Dec;30(12):4819-28.
18. L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. Kaira K, etal., Anticancer Res. 2011 Dec;31(12):4075-82.
19. Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence. Kaira K, etal., Anticancer Res. 2011 Nov;31(11):3775-82.
20. Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. Kaira K, etal., BMC Cancer. 2013 Oct 16;13:482. doi: 10.1186/1471-2407-13-482.
21. l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Kaira K, etal., Cancer Sci. 2008 Dec;99(12):2380-6. doi: 10.1111/j.1349-7006.2008.00969.x. Epub 2008 Nov 17.
22. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Kaira K, etal., Cancer Sci. 2009 Feb;100(2):248-54. doi: 10.1111/j.1349-7006.2008.01029.x.
23. CD98 is a promising prognostic biomarker in biliary tract cancer. Kaira K, etal., Hepatobiliary Pancreat Dis Int. 2014 Dec;13(6):654-7. doi: 10.1016/s1499-3872(14)60278-2.
24. Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma. Kaira K, etal., Hum Pathol. 2019 Feb;84:142-149. doi: 10.1016/j.humpath.2018.09.020. Epub 2018 Oct 6.
25. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Kaira K, etal., Lung Cancer. 2009 Oct;66(1):120-6. doi: 10.1016/j.lungcan.2008.12.015. Epub 2009 Jan 26.
26. Clinicopathological significance of L-type amino acid transporter 1 (LAT1) expression in patients with adenoid cystic carcinoma. Kaira K, etal., Pathol Oncol Res. 2013 Oct;19(4):649-56. doi: 10.1007/s12253-013-9624-2. Epub 2013 Mar 21.
27. Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Kaira K, etal., Pathol Res Pract. 2008;204(8):553-61. doi: 10.1016/j.prp.2008.02.003. Epub 2008 Apr 28.
28. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). Kanai Y, etal., J Biol Chem 1998 Sep 11;273(37):23629-32.
29. Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. Kobayashi H, etal., J Surg Oncol. 2005 Jun 15;90(4):233-8. doi: 10.1002/jso.20257.
30. Ultrastructural immunohistochemical study of L-type amino acid transporter 1-4F2 heavy chain in tumor microvasculatures of N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) induced rat bladder carcinoma. Kume E, etal., Microscopy (Oxf). 2017 Jun 1;66(3):198-203. doi: 10.1093/jmicro/dfx008.
31. Characteristics of L-citrulline transport through blood-brain barrier in the brain capillary endothelial cell line (TR-BBB cells). Lee KE and Kang YS, J Biomed Sci. 2017 May 10;24(1):28. doi: 10.1186/s12929-017-0336-x.
32. The impact of L-type amino acid transporter 1 (LAT1) in human hepatocellular carcinoma. Li J, etal., Tumour Biol. 2013 Oct;34(5):2977-81. doi: 10.1007/s13277-013-0861-5. Epub 2013 May 22.
33. Expression of a system L neutral amino acid transporter at the blood-brain barrier. Matsuo H, etal., Neuroreport. 2000 Nov 9;11(16):3507-11. doi: 10.1097/00001756-200011090-00021.
34. Up-regulation of L-type amino acid transporter 1 (LAT1) in cultured rat retinal capillary endothelial cells in response to glucose deprivation. Matsuyama R, etal., Drug Metab Pharmacokinet. 2012;27(3):317-24. doi: 10.2133/dmpk.dmpk-11-rg-122. Epub 2011 Dec 20.
35. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
36. Possible involvement of oxidative stress in piperonyl butoxide induced hepatocarcinogenesis in rats. Muguruma M, etal., Toxicology. 2007 Jul 1;236(1-2):61-75. doi: 10.1016/j.tox.2007.03.025. Epub 2007 Apr 6.
37. Induction of amino acid transporters expression by endurance exercise in rat skeletal muscle. Murakami T and Yoshinaga M, Biochem Biophys Res Commun. 2013 Oct 4;439(4):449-52. doi: 10.1016/j.bbrc.2013.08.094. Epub 2013 Sep 7.
38. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Nawashiro H, etal., Int J Cancer. 2006 Aug 1;119(3):484-92. doi: 10.1002/ijc.21866.
39. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
40. The human NAD metabolome: Functions, metabolism and compartmentalization. Nikiforov A, etal., Crit Rev Biochem Mol Biol. 2015;50(4):284-97. doi: 10.3109/10409238.2015.1028612. Epub 2015 Apr 2.
41. Diagnostic usefulness of ¹⁸F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma. Nobusawa A, etal., Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1692-700. doi: 10.1007/s00259-013-2477-9. Epub 2013 Jun 26.
42. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Oda K, etal., Cancer Sci. 2010 Jan;101(1):173-9. doi: 10.1111/j.1349-7006.2009.01386.x. Epub 2009 Oct 8.
43. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models. Ohkame H, etal., J Surg Oncol. 2001 Dec;78(4):265-71; discussion 271-2. doi: 10.1002/jso.1165.
44. Preferential expression of L-type amino acid transporter 1 in ameloblasts during rat tooth development. Park JC, etal., Anat Histol Embryol. 2004 Apr;33(2):119-24. doi: 10.1111/j.1439-0264.2003.00524.x.
45. Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Park YY, etal., Hepatology. 2016 Jan;63(1):159-72. doi: 10.1002/hep.28223. Epub 2015 Nov 26.
46. Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. Piao L, etal., J Mol Med (Berl). 2013 Oct;91(10):1185-97. doi: 10.1007/s00109-013-1064-7. Epub 2013 Jun 21.
47. SMPDB Annotation Import Pipeline Pipeline to import SMPDB annotations from SMPDB into RGD
48. GOA pipeline RGD automated data pipeline
49. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
50. Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation. Roberts LM, etal., Neuroscience. 2008 Aug 13;155(2):423-38. Epub 2008 Jun 13.
51. Positive correlation of expression of L-type amino-acid transporter 1 with colorectal tumor progression and prognosis: Higher expression in sporadic colorectal tumors compared with ulcerative colitis-associated neoplasia. Sakata T, etal., Pathol Res Pract. 2020 Jun;216(6):152972. doi: 10.1016/j.prp.2020.152972. Epub 2020 Apr 18.
52. TA1, a highly conserved oncofetal complementary DNA from rat hepatoma, encodes an integral membrane protein associated with liver development, carcinogenesis, and cell activation. Sang J, etal., Cancer Res 1995 Mar 1;55(5):1152-9.
53. Expression of TA1, a rat oncofetal cDNA with homology to transport-associated genes, in carbon-tetrachloride-induced liver injury. Shultz VD, etal., Pathobiology. 1997;65(1):14-25. doi: 10.1159/000164099.
54. TA1 oncofetal rat liver cDNA and putative amino acid permease: temporal correlation with c-myc during acute CCl4 liver injury and variation of RNA levels in response to amino acids in hepatocyte cultures. Shultz VD, etal., Toxicol Appl Pharmacol. 1999 Jan 1;154(1):84-96. doi: 10.1006/taap.1998.8555.
55. Expression of L-type amino acid transporter 1 in a rat model of liver metastasis: positive correlation with tumor size. Tamai S, etal., Cancer Detect Prev. 2001;25(5):439-45.
56. L-type amino acid transporter 1-mediated L-leucine transport at the inner blood-retinal barrier. Tomi M, etal., Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2522-30. doi: 10.1167/iovs.04-1175.
57. Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer. Toyoda M, etal., Br J Cancer. 2014 May 13;110(10):2506-13. doi: 10.1038/bjc.2014.178. Epub 2014 Apr 24.
58. Up-regulation of L type amino acid transporter 1 after spinal cord injury in rats. Toyooka T, etal., Acta Neurochir Suppl. 2008;102:385-8. doi: 10.1007/978-3-211-85578-2_74.
59. LAT-1 functions as a promotor in gastric cancer associated with clinicopathologic features. Wang J, etal., Biomed Pharmacother. 2013 Oct;67(8):693-9. doi: 10.1016/j.biopha.2013.05.003. Epub 2013 Jun 14.
60. Circ-SLC7A5, a potential prognostic circulating biomarker for detection of ESCC. Wang Q, etal., Cancer Genet. 2020 Jan;240:33-39. doi: 10.1016/j.cancergen.2019.11.001. Epub 2019 Nov 5.
61. Endotoxin-induced inflammation down-regulates L-type amino acid transporter 1 (LAT1) expression at the blood-brain barrier of male rats and mice. Wittmann G, etal., Fluids Barriers CNS. 2015 Sep 4;12:21. doi: 10.1186/s12987-015-0016-8.
62. High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas. Yanagisawa N, etal., Cancer Med. 2014 Oct;3(5):1246-55. doi: 10.1002/cam4.272. Epub 2014 Jun 2.
63. Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma. Yazawa T, etal., Am J Transl Res. 2015 Jun 15;7(6):1126-39. eCollection 2015.
64. Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment. Yothaisong S, etal., Tumour Biol. 2017 Mar;39(3):1010428317694545. doi: 10.1177/1010428317694545.
65. MicroRNA-194 participates in endotoxemia induced myocardial injury via promoting apoptosis. Zhai Y and Ding N, Eur Rev Med Pharmacol Sci. 2018 Apr;22(7):2077-2083. doi: 10.26355/eurrev_201804_14739.
Additional References at PubMed
PMID:15659399   PMID:17762180   PMID:19946888   PMID:20458337   PMID:25002582   PMID:25998567   PMID:29688723   PMID:30867591   PMID:33540026   PMID:35048187  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.21949,935,220 - 49,963,823 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1949,935,220 - 49,963,823 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1956,727,676 - 56,756,167 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01957,410,169 - 57,438,773 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01959,626,276 - 59,654,767 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01954,693,959 - 54,722,563 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1954,693,959 - 54,722,563 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01965,412,970 - 65,441,647 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41952,120,728 - 52,149,332 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11952,125,608 - 52,154,213 (-)NCBI
Celera1949,180,586 - 49,208,780 (-)NCBICelera
Cytogenetic Map19q12NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh381687,830,023 - 87,869,507 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl1687,830,023 - 87,869,507 (-)EnsemblGRCh38hg38GRCh38
GRCh371687,863,629 - 87,903,113 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 361686,421,130 - 86,460,601 (-)NCBINCBI36Build 36hg18NCBI36
Build 341686,421,130 - 86,460,601NCBI
Celera1672,160,934 - 72,200,417 (-)NCBICelera
Cytogenetic Map16q24.2NCBI
HuRef1673,604,119 - 73,643,626 (-)NCBIHuRef
CHM1_11689,274,981 - 89,314,543 (-)NCBICHM1_1
T2T-CHM13v2.01693,902,734 - 93,942,286 (-)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm398122,607,885 - 122,634,425 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl8122,607,889 - 122,634,433 (-)EnsemblGRCm39 Ensembl
GRCm388121,881,146 - 121,907,686 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl8121,881,150 - 121,907,694 (-)EnsemblGRCm38mm10GRCm38
MGSCv378124,405,046 - 124,431,586 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv368121,952,557 - 121,979,440 (-)NCBIMGSCv36mm8
MGSCv368124,767,240 - 124,802,593 (-)NCBIMGSCv36mm8
Celera8126,102,885 - 126,145,803 (-)NCBICelera
Cytogenetic Map8E1NCBI
cM Map870.8NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_0049555412,103,384 - 2,130,310 (-)EnsemblChiLan1.0
ChiLan1.0NW_0049555412,103,437 - 2,129,668 (-)NCBIChiLan1.0ChiLan1.0
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
NHGRI_mPanPan116103,515,885 - 103,556,386 (-)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v01668,512,407 - 68,552,763 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.11687,827,058 - 87,854,154 (-)NCBIpanpan1.1PanPan1.1panPan2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.1565,313,105 - 65,343,858 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl565,313,105 - 65,343,858 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha565,323,236 - 65,353,508 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0565,532,866 - 65,563,141 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl565,532,793 - 65,565,302 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.1565,558,337 - 65,588,569 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0565,390,029 - 65,420,262 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0565,797,114 - 65,827,358 (+)NCBIUU_Cfam_GSD_1.0
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_02440934925,759,563 - 25,783,919 (+)NCBIHiC_Itri_2
SpeTri2.0NW_0049366411,513,110 - 1,538,955 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl61,545,944 - 1,574,285 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.161,545,940 - 1,574,298 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
ChlSab1.1573,229,953 - 73,269,801 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl573,229,951 - 73,269,754 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_0236660472,438,818 - 2,479,135 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla 1.0NW_0046247461,325,368 - 1,349,616 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Slc7a5
74 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:789
Count of miRNA genes:299
Interacting mature miRNAs:383
Prediction methods:Microtar, Miranda
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
724566Uae12Urinary albumin excretion QTL 125urine albumin amount (VT:0002871)urine albumin level (CMO:0000130)19218792756457239Rat
1331737Uae29Urinary albumin excretion QTL 295.5urine albumin amount (VT:0002871)urine albumin level (CMO:0000130)19409615555283277Rat
7411549Bw130Body weight QTL 13050.001body mass (VT:0001259)body weight gain (CMO:0000420)191545586057337602Rat
1578764Stresp19Stress response QTL 193.60.001blood renin amount (VT:0003349)plasma renin activity level (CMO:0000116)191563020157337602Rat
2298478Eau8Experimental allergic uveoretinitis QTL 80.0163uvea integrity trait (VT:0010551)experimental autoimmune uveitis score (CMO:0001504)191715443357337602Rat
61350Bp32Blood pressure QTL 320.012arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)192048357557337602Rat
724546Kidm3Kidney mass QTL 33.1kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)192932249057337602Rat
1358200Insglur2Insulin/glucose ratio QTL 24.1blood glucose amount (VT:0000188)serum insulin level (CMO:0000358)193383821455283146Rat
1358200Insglur2Insulin/glucose ratio QTL 24.1blood glucose amount (VT:0000188)serum glucose level (CMO:0000543)193383821455283146Rat
5135224Leukc1Leukocyte quantity QTL 1eosinophil quantity (VT:0002602)blood eosinophil count (CMO:0000033)194434021455283277Rat


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
Medium 3 24 32 26 17 26 74 18 37 2
Low 19 25 15 2 15 7 9 17 4 9 7
Below cutoff 1 2 1


RefSeq Acc Id: ENSRNOT00000025784   ⟹   ENSRNOP00000025784
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1949,935,220 - 49,963,823 (-)Ensembl
Rnor_6.0 Ensembl1954,693,959 - 54,722,563 (-)Ensembl
RefSeq Acc Id: NM_017353   ⟹   NP_059049
Rat AssemblyChrPosition (strand)Source
mRatBN7.21949,935,220 - 49,963,823 (-)NCBI
Rnor_6.01954,693,959 - 54,722,563 (-)NCBI
Rnor_5.01965,412,970 - 65,441,647 (-)NCBI
RGSC_v3.41952,120,728 - 52,149,332 (-)RGD
Celera1949,180,586 - 49,208,780 (-)RGD
Protein Sequences
Protein RefSeqs NP_059049 (Get FASTA)   NCBI Sequence Viewer  
GenBank Protein AAA74411 (Get FASTA)   NCBI Sequence Viewer  
  AAK16501 (Get FASTA)   NCBI Sequence Viewer  
  BAA33035 (Get FASTA)   NCBI Sequence Viewer  
  EDL92732 (Get FASTA)   NCBI Sequence Viewer  
Ensembl Protein ENSRNOP00000025784
GenBank Protein Q63016 (Get FASTA)   NCBI Sequence Viewer  
RefSeq Acc Id: NP_059049   ⟸   NM_017353
- UniProtKB: Q9QWL4 (UniProtKB/Swiss-Prot),   Q63016 (UniProtKB/Swiss-Prot),   A6IZQ4 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000025784   ⟸   ENSRNOT00000025784

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-Q63016-F1-model_v2 AlphaFold Q63016 1-512 view protein structure


eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

RGD ID:13701201
Promoter ID:EPDNEW_R11723
Type:single initiation site
Description:solute carrier family 7 member 5
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database,
Experiment Methods:Single-end sequencing.
Rat AssemblyChrPosition (strand)Source
Rnor_6.01954,722,580 - 54,722,640EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:620639 AgrOrtholog
BioCyc Gene G2FUF-5414 BioCyc
Ensembl Genes ENSRNOG00000018824 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000025784 ENTREZGENE, UniProtKB/Swiss-Prot
Gene3D-CATH Amino acid/polyamine transporter I UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro AA/rel_permease1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  L_AA_transporter UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:50719 UniProtKB/Swiss-Prot
Pfam AA_permease_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Slc7a5 PhenoGen
PIRSF AA_transporter UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
RatGTEx ENSRNOG00000018824 RatGTEx
UniProt Secondary Q9QWL4 UniProtKB/Swiss-Prot

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2016-02-24 Slc7a5  solute carrier family 7 member 5  Slc7a5  solute carrier family 7 (amino acid transporter light chain, L system), member 5  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2011-08-01 Slc7a5  solute carrier family 7 (amino acid transporter light chain, L system), member 5  Slc7a5  solute carrier family 7 (cationic amino acid transporter, y+ system), member 5  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2006-03-30 Slc7a5  solute carrier family 7 (cationic amino acid transporter, y+ system), member 5    tumor-associated protein 1  Name updated 1299863 APPROVED
2004-09-10 Slc7a5  tumor-associated protein 1  TA1    Symbol and Name updated 1299863 APPROVED
2002-08-07 TA1  tumor-associated protein 1      Symbol and Name status set to provisional 70820 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_domains contains multiple hydrophobic transmembrane domains 634202
gene_expression expressed in the normal adult rat tissues including testes, brain, ovary, spleen, mammary gland, and uterus; differentially expressed between hepatoma cells and normal liver 634202
gene_process human cDNA is associated with lymphocyte activation 634202